Cochrane · systematic review · CD013611
Vedolizumab for induction and maintenance of remission in Crohn's disease
Hui, S, Sinopoulou, V, Gordon, M, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 2 · 28.6%High 3 · 42.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Vedolizumab compared to placebo for induction of remission in Crohn's disease
Population: children or adults with Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Induction of clinical remission (6–10 weeks) Vedolizumab vs placebo | RR 1.61 [1.2, 2.17] | 4 studies · 1126 participants | High |
Induction of clinical response (6–10 weeks) Vedolizumab vs placebo | RR 1.43 [1.19, 1.71] | 4 studies · 1126 participants | High |
Adverse events (6–10 weeks) Vedolizumab vs placebo | RR 1.01 [0.93, 1.11] | 4 studies · 1126 participants | Moderate Downgraded: risk of bias, imprecision |
Serious adverse events (6–10 weeks) Vedolizumab vs placebo | RR 0.91 [0.62, 1.33] | 4 studies · 1126 participants | Low Downgraded: risk of bias, imprecision |
Vedolizumab compared to placebo for maintenance of remission in Crohn's disease
Population: children or adults with Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maintenance of clinical remission (52–60 weeks) Vedolizumab vs placebo | RR 1.52 [1.24, 1.87] | 3 studies · 894 participants | High |
Adverse events (52–60 weeks) Vedolizumab vs placebo | RR 1 [0.94, 1.07] | 3 studies · 894 participants | Moderate Downgraded: imprecision |
Serious adverse events (52–60 weeks) Vedolizumab vs placebo | RR 0.98 [0.68, 1.39] | 3 studies · 894 participants | Low Downgraded: imprecision |